Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)

Trial Profile

A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ianalumab (Primary) ; Iscalimab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals

Most Recent Events

  • 28 Jun 2024 The study has been Completed in Germany, According to European Clinical Trials Database record.
  • 15 Jun 2024 Results assessing changes in B-cell subsets, whole blood transcriptome and antibodies against extractable nuclear antigens (ENA) in patients with systemic lupus erythematosus (SLE) pre- and post-treatment with ianalumab to characterize pharmacodynamic (PD) biomarkers and biological pathways linked to mechanism of action and clinical response presented at the 25th Annual Congress of the European League Against Rheumatism
  • 15 Jun 2024 Results (n=67) reporting longer-term data from additional 24-week open-label ianalumab treatment portion of this trial presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top